Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig in Advanced Extrapulmonary Neuroendocrine Cancer
NCT07544654Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 29
01
Overview
A Phase 3 trial of obrixtamig in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Boehringer Ingelheim. Started Jul 2026; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07544654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544654.